In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe® panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe® panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe® NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice.

Nacchio M., Sgariglia R., Gristina V., Pisapia P., Pepe F., de Luca C., et al. (2020). KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting. JOURNAL OF THORACIC DISEASE, 12(7), 3836-3843 [10.21037/jtd.2020.01.19].

KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting

Gristina V.;Russo A.;
2020

Abstract

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe® panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe® panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe® NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice.
Settore MED/06 - Oncologia Medica
Nacchio M., Sgariglia R., Gristina V., Pisapia P., Pepe F., de Luca C., et al. (2020). KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting. JOURNAL OF THORACIC DISEASE, 12(7), 3836-3843 [10.21037/jtd.2020.01.19].
File in questo prodotto:
File Dimensione Formato  
KRAS mutations testing in non-small cell lung cancer.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 376.88 kB
Formato Adobe PDF
376.88 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/433147
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact